{"filing":{"accession_number":"0001493152-26-033514","cik":"0000946644","ticker":"AIM","company_name":"AIM ImmunoTech Inc.","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226033514/form8-k.htm"},"events":[{"id":18399,"run_id":16539,"accession_number":"0001493152-26-033514","anchor_item_number":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This 8-K Item 5.07 discloses the results of a Special Meeting of Stockholders held on July 15, 2026, with voting results on seven proposals. The filing reports final vote tallies from the Inspector of Elections for each proposal, including approval of warrant issuances exceeding 19.99% of outstanding shares (Proposals 1-5), authorization for a reverse stock split (Proposal 6), and meeting adjournment authority (Proposal 7). All proposals were approved. The warrant issuances and reverse split authorization are material capital structure events requiring shareholder approval under NYSE American rules.","company_name":"AIM ImmunoTech Inc.","ticker":"AIM","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":17197,"accession_number":"0001493152-26-033514","item_number":null,"item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This 8-K Item 5.07 discloses the results of a Special Meeting of Stockholders held on July 15, 2026, with voting results on seven proposals. The filing reports final vote tallies from the Inspector of Elections for each proposal, including approval of warrant issuances exceeding 19.99% of outstanding shares (Proposals 1-5), authorization for a reverse stock split (Proposal 6), and meeting adjournment authority (Proposal 7). All proposals were approved. The warrant issuances and reverse split authorization are material capital structure events requiring shareholder approval under NYSE American rules.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:07:20.619202+00:00","company_name":"AIM ImmunoTech Inc.","ticker":"AIM","filing_date":"2026-07-16"}]}